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A B S T R A C T
The radial approach is considered alternative to the traditional femoral approach to 
perform coronary angiography and percutaneous coronary intervention (PCI). Tran-
sradial compared to transfemoral PCI has been consistently shown to be equally ef-
fective but safer, since it significantly reduces access site related and bleeding com-
plications. Additionally, it increases patient comfort and reduces hospitalization cost. 
Modern interventional strategies and aggressive antithrombotic regimens have lim-
ited ischemic adverse events following PCI. At the downside, bleeding complications 
remain a serious problem and adversely affect outcomes. They can be reduced with 
novel pharmacologic agents but still have unacceptably high rates and are mostly re-
lated to femoral access. In this context the radial approach seems a reasonable choice 
to further reduce access related bleeding. A concise overview of recent data support-
ing a more widespread dissemination of transradial PCI and a brief presentation of 
the most important pertinent technical issues are attempted herein.
I N T R O D U C T I O N
Percutaneous coronary intervention (PCI) can be performed via the femoral, 
brachial, or radial arteries. The femoral approach has traditionally been and still is 
the primary approach for most operators. Campeau et al first described the radial 
approach for coronary angiography in 1989.1 The first transradial PCI was reported 
by Kiemeneij and Laarman in 1993.2 Later, their group published the first series of 
balloon angioplasty and bare-metal stent implantation performed through the radial 
artery.3,4 Transradial compared to classic transfemoral PCI has been shown to have 
similar efficacy rates, while being more cost-effective and most importantly safer 
due to fewer access site or bleeding complications.5 Furthermore, patient comfort is 
increased and outpatient treatment may be feasible.6,7 However, the penetration of 
radial approach is heterogeneous worldwide. It is mostly developed in northwestern 
Europe, Canada and Eastern Asia. Especially in France 60% of PCI procedures are 
performed transradially, while in Europe the percentage currently is around 20%.8 
Despite the presence of dedicated radialists, utilization of the radial approach in the 
U.S. remains quite low. As recently reported by Rao et al the percentage of radial 
PCIs increased from approximately 1.3% to only 3.5% by the first quarter of 2007 for 
centers participating in the National Cardiovascular Data Registry database.9 This is 
largely due to lack of widespread training and subsequent trepidation involving the 
learning curve.10
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R A D I A L  V E R S U S  F E M O R A L  A P P R O A C H
Since first described in 1989, multiple studies have shown 
a lower rate of access site complications and major bleeding 
with the radial approach. In the first randomized comparison 
of elective PCI via the radial, brachial or femoral approaches, 
Kiemeneij et al found similar procedural success regardless of 
strategy but a significantly lower risk of access site complica-
tions in the radial group (no complications in the radial group 
compared with 2.3% and 2.0% in the brachial and femoral 
groups, p=0.035).11 Subsequently several randomized trials 
have consistently demonstrated that radial access reduces 
access site complications compared to femoral approach. One 
of the largest meta-analysis comparing radial versus femoral 
approach for diagnostic catheterization and interventional 
procedures by Agostoni et al included 12 randomized trials 
(3224 patients). Major adverse cardiovascular events were 
similar between radial and femoral groups (2.1 vs. 2.4%, OR: 
0.92, p=0.7). The radial approach was superior to the femoral 
approach regarding entry site complications (0.3 vs. 2.8%; OR: 
0.20, p = 0.0001), mean hospital stay (1.8 days vs. 2.4 days, 
p <0.001) and lower total hospital charge. Conversely, radial 
access was associated with a significantly higher number of 
procedural failures in comparison to femoral access (7.2 vs 
2.4%; OR: 3.30, p =0.001), as well as longer fluoroscopy time 
(8.9 versus 7.8 min, P <0.001). Of note, procedural failure was 
significantly reduced after 1999 indicating increased operator 
experience.5
The single greatest advantage of the radial approach is 
reduced bleeding and vascular access complications. Every 
center that predominantly performs the radial technique 
delight in reporting no retroperitoneal hematomas, femoral 
pseudoaneurysms, fistula, painful large hematomas, artery 
occlusions, or emboli.7 The analysis by Rao et al reviewed data 
from the National Cardiovascular Data Registry from 2004 to 
2007 and indicated significantly lower bleeding with the radial 
approach compared to femoral (OR: 0.42) with similar success 
rate.9 These advantages extend to elderly patients also, as sug-
gested by Achenbach et al in their randomized trial involving 
patients more than 75 years of age.12 The rate of major com-
plications (bleeding requiring surgery or transfusion, stroke) 
was 0% for the radial and 3.2% for the femoral approach 
(p< 0.001).12 Jolly et al in a recent meta-analysis found that 
radial artery access reduced major bleeding 73% compared to 
femoral (0.05% vs. 2.3%, p=0.001) and interestingly identified 
a trend for reductions in the composite of death, myocardial 
infarction, and stroke (2.5% vs. 3.8%, p=0.058).13 There was 
no difference in death alone between the 2 techniques. For 
PCI, a higher trend for inability to cross lesions from radial 
compared with femoral access was noted (p=0.21). Radial 
access reduced hospital stay by 0.4 days (p=0.001) and was 
associated with reduced major bleeding and strong trends for 
reduction in ischemic events compared with femoral artery ac-
cess. These findings differ from the meta-analysis of Agostoni 
et al performed in 2004, which showed similar rates of major 
adverse cardiac events with radial access (death, MI, stroke, 
emergent PCI, or coronary artery bypass surgery).5 This may 
be due to the fact that the 2009 meta-analysis by Jolly et al 
had increased power with the addition of 5 randomized trials 
(3 of which were in STEMI) composed of more than 2000 
additional patients.13
Recently Brueck et al presented another detailed study 
randomizing 1024 patients to one of the two vascular access 
methods.14 Femoral access had slightly higher procedural suc-
cess rates (97% transradial, 99.8% transfemoral, p=0.0001). 
The radial approach had longer procedure times (40 min vs 
37 min), and slightly more radiation exposure (42 Gy/cm2 vs 38 
Gy/cm2). Unique to this study compared with other reports is 
the fact that despite the use of femoral vascular access closure 
devices (used in 93% of PCI patients), the femoral group still 
had 6 times more vascular access site complications (3.7% vs. 
0.6%, p=0.0008) compared with the radial group.
T R A N S R A D I A L  P C I  I N  A C U T E 
C O R O N A R Y  S Y N D R O M E S  ( A C S )
Femoral access bleeding complications remain an impor-
tant cause of morbidity and mortality in patients undergoing 
PCI.15 Femoral closure devices have had an impact since 
femoral sheaths may be removed immediately with their use. 
However, they have not solved the problem because these 
devices even in experienced hands have not been found to 
reduce the rate of hemorrhagic or vascular complications in 
randomized trials.16,17 A recent study by Sciahbasi et al showed 
significant reduction of access site bleeding with the radial 
approach compared to femoral even when vascular closure 
devices were used. Radial access significantly reduced major 
complications (0.7%) compared with manual compression 
(2.9%, p=0.03) or vascular closure devices [StarClose® 2.7%, 
AngioSeal® 3.9%, p=0.003].18 The major advantage of tran-
sradial PCI is the near elimination of clinically significant 
access site complications, even in patients at high risk (ie, 
patients treated with GP IIb/IIIa inhibitors or shortly after 
systemic thrombolysis).
In ACS patients the rate of major bleeding is between 
3 to 5%.19,20 Bleeding events and the consequent need for 
transfusion are independent determinants of survival and 
their relation to short- and long-term mortality has been 
demonstrated in major randomized trials as well as through 
the evaluation of registries.21-23 As shown by Bertrand et al in 
a cohort of 1348 patients with ACS all treated by transradial 
PCI and maximal antiplatelet therapy the incidence of major 
bleeding was low (1.4%).24 In patients with major bleeding, 
the incidence of major adverse cardiac events was higher at 
30 days (37% vs 3%), 6 months (42% vs 8%), and 12 months 
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(53% vs 12%, p <0.0001 for all comparisons) and the conclu-
sion was that major bleeding is an independent predictive 
factor of adverse acute and 1-year outcomes, regardless of 
the access site.24 Possible mechanisms of worse outcome after 
a bleeding event might include bleeding-induced imbalance 
of the coagulant/anticoagulant mechanisms (consumption of 
the anticoagulant proteins, higher platelet turnover), adverse 
effects induced by transfusion, and premature cessation of 
antithrombotic/anticoagulant therapy.13
For ACS patients interventional and pharmacological 
advances have now reduced ischemic complications to the 
point that reduction in bleeding events should become the 
primary target to further improve PCI outcomes.22,25 Obviat-
ing bleeding seems equally important as recurrent ischemic 
events after PCI.26 This fact has lead to testing of newer 
pharmacologic agents in the setting of acute coronary syn-
dromes to decrease bleeding complications while preserving 
efficacy in preventing ischemic events.27,28 However, despite the 
introduction of these newer pharmacologic agents, bleeding 
complications at the puncture site represented almost 50% of 
all hemorrhagic complications, and the best option to prevent 
them was considered the radial approach.29 In the ACUITY 
trial, 13819 patients with moderate and high-risk ACS were 
randomized to either heparin (unfractionated or enoxaparin) 
plus a GP IIb/IIIa inhibitor, bivalirudin plus a GP IIb/IIIa 
inhibitor, or bivalirudin alone. The use of bivalirudin alone 
resulted in comparable rates of ischemic events, significantly 
fewer major bleeding complications, and superior net clinical 
outcomes compared to combination therapy with unfraction-
ated heparin or enoxaparin plus GP IIb/IIIa inhibitor.27 Per 
operator choice, femoral access was used in 11989 patients 
(93.8%) and radial access in 798 patients (6.2%). In a post 
hoc analysis of the ACUITY trial, bivalirudin monotherapy 
compared to heparin plus GP IIb/IIIa inhibitor significantly 
reduced access site related major bleeding complications with 
femoral but not radial artery access, though non-access site 
related bleeding is reduced by bivalirudin monotherapy in all 
patients.30 Thus beyond pharmacologic agents and regimens 
shown to reduce bleeding, the radial approach should be 
considered as a simple and cost effective strategy to addition-
ally prevent major bleeding or other complications associated 
with femoral access.
Despite the potential advantage of radial approach, no 
clinical randomized trials have been conducted to evaluate 
whether it might impact on the prognosis of patients with 
ACS compared with other vascular accesses. Reduction of the 
frequency of bleeding and mortality by using the radial ap-
proach has been recently demonstrated in a large PCI registry 
study.23 The MORTAL study retrospectively examined the 
association between access site, transfusion, and outcomes in 
over 32000 patients who underwent PCI in British Columbia 
from 1999 to 2005. The main finding was that by reducing 
vascular access site complications, the use of the radial ac-
cess site was associated with a 50% reduction in transfusion 
rate and a relative reduction in 30-day and 1-year mortality 
of 29% and 17%, respectively (p<0.001), which corresponds 
to around 1% absolute risk reduction at one year.23 Similarly, 
in the PRESTO-ACS observational study that included over 
a thousand non-ST-segment elevation ACS patients it has 
been shown that the radial group had a statistically significant 
decrease in death or re-infarction (4.9 vs. 8.3%, p=0.05) and 
bleeding (0.7 vs. 2.7%, p=0.03) at 1-year follow-up.31 In this 
study the rate of bleeding complications in the radial group 
was only 0.7%, an incidence lower than that derived from pub-
lished reports with the use of bivalirudin (3%) or fondaparinux 
(2.4%) and a femoral approach.27,32 However, as is the case for 
observational studies, potential biases might have played a role 
in the selection of patients in these two studies, with patients 
considered at lower risk scheduled for radial and patients at 
higher risk scheduled for femoral approach. Thus, definite 
conclusions cannot be drawn, but they could represent good 
hypothesis-generating studies for randomized trials.
The two largest comprehensive meta-analyses of rand-
omized comparisons of radial and femoral accesses demon-
strated that radial access reduces bleeding and access site 
complications.5,13 Neither of them found a significant link 
between the frequency of adverse events or mortality. It should 
be noted that these analyses included studies performed pre-
dominantly in elective settings and thus the potential benefits 
for the higher risk patients could have been concealed by the 
lower risk-cases that formed the majority. Clinical trials, such 
as OASIS-5 and HORIZONS-AMI have shown that thera-
pies that reduce bleeding also reduce mortality and ischemic 
outcomes.28,32 The CURRENT-OASIS 7 study includes a 
femoral versus radial access sub-study with more than 2000 
randomized patients, which is expected to confirm or refute 
the hypothesis that radial access is better than femoral ac-
cess not only in reduction of access site bleeding but also for 
ischemic events.33
T R A N S R A D I A L  P R I M A R Y  P C I
Back in 1996 Steg and Aubry reported two transradial pri-
mary PCIs in patients with severe peripheral arterial disease.34 
A similar case of transradial primary PCI due to impossible 
femoral access is described in Figure 1 (unpublished recent 
case from our institution). Low incidence of vascular access 
site bleeding complications suggests that the radial approach 
may be a safe alternative to the femoral technique in acute 
myocardial infarction with ST-segment elevation (STEMI), 
particularly when an aggressive anticoagulation and antiplate-
let regimen is applied. In the recent metanalysis of Jolly and 
al, the major bleeding absolute risk reduction for studies that 
included coronary interventions was 1.8% (p = 0.001), yielding 
a number needed to treat of 56 patients to prevent one major 
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bleeding event.13 Interestingly, the greatest absolute benefit 
appeared in the setting of primary or rescue angioplasty for 
STEMI with an absolute risk reduction of 3.1% (p= 0.001).13 
However, the possible greater occurrence of procedural failure 
and longer procedural times occasioned by difficulty in punc-
turing the radial artery, inability to cannulate the coronaries, 
or impossibility to perform the angioplasty are factors that 
raise distrust as to whether radial access remains beneficial in 
a setting where timely reperfusion is critical as in STEMI.
In the prospective multi-center randomized TEMPURA 
study comprising 149 patients, Saito et al were the pioneers 
to report that the radial access was feasible and safe for pri-
mary PCI in patients with STEMI.35 They demonstrated that 
for selective patients with STEMI, the radial is comparable 
to femoral approach in terms of the reperfusion success rate 
and the incidence of in-hospital major adverse clinical events. 
The choice of arterial access route had no significant impact 
on the 30-day mortality rate. However, the combined vascular 
and bleeding complications were significantly less in the radial 
group.35 Other registry studies have also reported superior re-
sults. Louvard et al were able to demonstrate the efficacy and 
safety of transradial primary PCI in a prospective two-center 
registry of 277 cases.36 Intervention was successful in >95% 
of both radial and femoral access patients. Total procedural 
time did not differ between the two groups. However, severe 
access site-related bleeding complications, were observed 
in femoral group patients only.36 Cruden et al were able to 
demonstrate in their retrospective analysis of 287 patients un-
dergoing rescue PCI that the radial route was associated with 
similar procedural success rate compared to femoral.37 There 
were no differences in procedural or in-hospital mortality, 
procedure duration, or radiation dose, but reduced vascular 
complications and post-procedural length of stay for patients 
who underwent transradial PCI.37 Recently Yip et al reported 
the results from a single-center observational analysis of 506 
transradial compared to 810 transfemoral primary PCI cases, 
FIGURE 1. Example of obligatory transradial primary PCI: Patient with acute inferior wall myocardial infarction with a history of 
longstanding bilateral intermittent claudication and absent femoral pulses. A. Right radial approach selected: occluded right coro-
nary artery at segment 2. B. After lesion crossing and balloon predilatation two tight lesions (segments 2 and 3) need stenting. C. 
Final result after implanting two stents. D and E. Several weeks later, scheduled PCI and stenting for a tight obtuse marginal lesion 
(D and E, before and after stenting respectively). F. At the same session aortography reveals aortic occlusion just below the renal 
arteries. Collaterals provided blood supply to the lower extremities. The patient was submitted to successful aorto-femoral by pass 
one month later. Previous experience from routine use of the radial approach for PCI is most valuable for such emergency cases with 
impossible femoral access.
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which is the largest number todate.38 Initial puncture to first 
balloon inflation time and rates of post procedure TIMI III 
flow in the infarct-related artery were similar in both groups. 
Although the 30-day mortality rate did not differ between the 
2 groups (4.9% vs 3.8%, p=0.341), the rate of combined major 
vascular and bleeding complications was higher in the femoral 
than in the radial access group (6.1% vs 0%, p<0.0001). Dura-
tion of hospital stay was also longer in the femoral group (6 
vs 3.3 days, p=0.032).
A recently published meta-analysis by Vorobcsuk et al, 
which included 12 studies comprising 3324 patients, demon-
strated that the transradial coronary intervention is highly 
effective and safe in the setting of STEMI for both primary 
and rescue PCI.39 There were no differences in procedural 
time and in time to reperfusion between the two access routes. 
Transradial PCI reduced major bleeding compared to trans-
femoral (0.77% vs 2.61%, OR 0.30, p=0.0001), and significant 
reductions were found in the composite of death, myocardial 
infarction, or stroke (3.65% vs 6.55%, OR 0.56, p =0.001). 
Mortality reduction showed a significant toward benefit in the 
case of transradial PCI (2.04% vs 3.06%, OR 0.54, p = 0.01). 
The fluoroscopic time was longer, and access site crossover 
was more frequent for the radial approach. Of note, patients 
suffering from cardiogenic shock and with need for intra-aortic 
balloon pump (IABP) insertion were generally excluded from 
these studies and treated via the femoral route.
T R A N S R A D I A L  P C I :  C O N C E R N S  
A N D  L I M I T A T I O N S
The radial approach has certain advantages and disadvan-
tages (Table 1). Before embarking on the radial approach for 
coronary intervention one should be aware of the technique’s 
drawbacks and limitations.
The learning curve for transradial is steeper than for 
transfemoral intervention.40 Crossover from radial to femoral 
access is significantly higher than in the opposite way.13 Punc-
ture failure, radial artery spasm, and tortuous brachiocephalic 
trunk are the most common reasons (Figure 2). In a large 
meta-analysis by Agostoni et al the overall rate of procedural 
failure was 7.2% in the radial group compared with 2.4% in 
the femoral (OR: 3.30, p=0.001).5 Louvard et al. reported a 
rate of 10% in the first 50 cases, 3% to 4% after other 500 
cases, whereas it stabilizes at less than 1% only after 1,000 
procedures.41 A recent report identified advanced age, prior 
coronary bypass surgery, and short stature as independent 
predictors of radial approach failure.42 In the meta-analysis 
by Jolly et al when studies were divided into those performed 
in the early era of radial access (prior to 1999), the odds of 
access site crossover with radial was 5-fold higher (OR 5.63, 
p <0.001) versus the modern era (1999-2008) where radial 
access had a 3-fold increase in access site crossover (OR 2.96, 
p <0.001, interaction p =0.04), suggesting that improvements 
in expertise and technology have narrowed the gap.13
Table 1. Advantages and disadvantages of the radial approach to PCI.
Advantages Disadvantages
Easy hemostasis at the end of the procedure. Long learning curve.
Negligible access site bleeding
(≤0.6% vs 3-4% with femoral approach).
Not advised in case of abnormal Allen test. Crossover rate to femoral 
approach more frequent than vice versa.
Negligible risk for arteriovenous fistula, pseudoaneurysm, 
retroperitoneal bleeding, painful hematoma or nerve damage.
Perceived longer procedure time and radiation exposure (operator 
dependent, mainly in the first part of the learning curve).
No ischemic complications in case of occlusion (3-6% of cases) if 
Allen test is not abnormal.
Risk of spasm. Difficult manipulation in case of tortuous 
brachiocephalic trunk. 
Better patient comfort, immediate ambulation. Sometimes movement of catheters with respiration, which can render 
stent positioning difficult.
Cost saving, outpatient procedures possible. Sometimes limited backup support requiring more manipulation 
(deep intubation possible, especially with 5F guiding catheters).
Ideal for certain patient subsets: obese, those who can not lie flat 
(heart failure, back pain, urinary retention), iliofemoral disease, 
abdominal aorta aneurysms with mural thrombus, if INR >2.
Limitations possible with interventional material: maximum catheter 
size 7F (only in large arteries), rotablator with larger burr sizes, some 
thrombus aspiration, debulking and distal protection devices.
Better guiding catheter back up for LIMA PCI with left radial 
approach.
Femoral access prefered if IABP or temporary pacemaker needed.
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The incidence of an abnormal Allen’s test in patients 
undergoing coronary angiography ranges from 6.4% to 
27%.43,44 The visual assessment of the Allen’s test has a limited 
specificity because of delayed recruitment of collateral flow. 
Studies using Doppler ultrasound, plethysmography, and pulse 
oximetry revealed a sufficient supply by the ulnar artery in 
most patients with a pathologic Allen’s test.44,45 However, an 
elevated thumb capillary lactate level was measured in these 
patients.46 Transradial catheterization should be avoided in 
the presence of an abnormal Allen’s test unless the risk of 
using the transfemoral approach is exceedingly increased 
(e.g., severe peripheral vascular disease, morbid obesity, large 
abdominal aortic aneurysm, Leriche syndrome).
The risk of transient or permanent radial artery occlusion 
with a normal Allen’s test is 5.3% and 2.8% respectively.47 
Medication is required to avoid vasospasm and thrombosis.48,49 
Patent hemostasis has been shown to decrease the incidence 
of radial artery occlusion which is directly related to the ratio 
between the sheath and artery size.50,51 Therefore, smaller 
guiding catheters are potentially advantageous leading to less 
arterial spasm, pain, and post-procedural vessel occlusion. 
However, it has been shown that during PCI 5 Fr catheters 
offer no advantages concerning radial artery occlusion as 
compared with 6 Fr catheters, with the drawback of a 7% 
crossover rate from 5 to 6 Fr.52 The suitability of the radial 
artery after transradial catheterization as a bypass conduit 
has been of great concern to surgeons. Although there were 
no redo angiographies through the same radial artery in the 
transradial group, it could be demonstrated by Kamiya et al 
and Yoo et al that after transradial catheterization the radial 
artery could be used for both coronary artery bypass surgery 
as an arterial graft and repeat catheterization.53,54
During transradial PCI some difficulty may be encoun-
tered due to reduced guiding catheter backup force, particu-
larly when using the Judkins catheter.55 The backup force is 
ruled by physics not by the approach site and is determined by 
the size and shape of the guiding catheter. Thus, less backup 
force of the guiding catheter can be overcome by using a 
properly shaped guiding catheter for transradial intervention, 
such as the Ikari.56
There are some technical concerns about transradial PCI 
for treating bifurcation lesions. A radial artery of patients 
less than 1.72 m tall can easily accommodate a 6 Fr sheath 
and a 6 Fr guide catheter, and patients taller than 1.72 m can 
accommodate a 7 Fr guide for an intervention. A bifurcation 
lesion with two wires in the main branch and side branch and 
subsequent provisional stenting and final balloon kissing 
can easily be performed in most patients using a 6 Fr guide 
catheter. In a recent meta-analysis of various randomized 
controlled trials for coronary bifurcation interventions Nic-
coli et al. showed that there was no association between the 
choice of the access site and the outcomes of the procedure.57 
The radial artery size restricts interventional device options in 
some cases. The femoral approach is the approach of choice 
when guiding catheters ≥7 Fr are required (simultaneous two 
stent deployment, large bore rotablation, some debulking, 
thrombus aspiration and distal protection devices). Femoral 
access is also prefered when IABP or temporary pacemaker 
is needed. To the contrary, pressure wire, intravascular ultra-
sound, individual stents, and the “kissing balloon” technique 
for the treatment of bifurcations can all be accommodated by 
modern 6 Fr guide catheters used transradially.
Difficult or tortuous anatomy can lead to longer proce-
dures with higher radiation exposure compared to similar 
femoral access procedures.58 In the meta-analysis by Jolly 
et al radial access was associated with a significantly longer 
procedural time with a mean difference of 3.1 min (p=0.001). 
However, there was significant heterogeneity with a larger 
difference in procedural time found in studies performed by 
non–radial experts compared to radial experts (mean differ-
ence 4.8 vs 1.7 minutes respectively, p <0.001).13 Similarly, 
in the above mentioned study by Brueck et al the procedural 
time in the radial group (40.2 min) was slightly longer than in 
the femoral approach group (37.0 min), but the difference was 
significant (p=0.048).14 However, under most circumstances it 
is unlikely that this time period would be clinically significant. 
Additionally, this time difference of 3.2 min did not include 
the time interval required for hemostasis, which may exceed 
15 min after transfemoral procedures. The time required to 
obtain hemostasis using the radial route is markedly shorter 
because manual compression is not necessary and a bandage 
can be applied immediately after the procedure. Therefore, 
FIGURE 2. Radial approach: severe tortuosity of brachiocephal-
ic trunk rendering impossible catheter advancement into the as-
cending aorta. Fortunately such a scenario is very rare (<1% of 
cases; may happen with elderly hypertensive patients).
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procedural time does not constitute a strong rationale in favor 
of femoral approach, especially for experienced operators. 
Fluoroscopy time, which is a surrogate of radiation dose, was 
significantly longer for radial access in the meta-analysis by 
Jolly et al., with mean difference of 0.4 minutes (p=0.001).13 
Brasselet et al. reported that the radiation exposure of the 
operator in a transradial approach was increased as well, 
despite using optimized specific protection devices, reflect-
ing technical difficulties and a slightly closer position of the 
interventional cardiologist to the X-ray source.58 There were 
important methodological issues with this study since it had 
a non-randomized design and a high probability that most of 
the operators were amidst their learning curve.59 Yet, reports 
showing increased radiation exposure are currently casting a 
shadow of caution on the radial approach. For the right radial 
approach operators usually use adapted catheterization-labo-
ratory suites where after sheath insertion they work at almost 
the same distance from the X-ray source as with conventional 
femoral route. With experience and overcoming the learning 
curve the procedural and fluoroscopy times between a femoral 
and radial case become very close.60
C O N C L U S I O N
Transradial PCI is feasible, effective and safe and can be 
applied in the majority of cases. The technique is limited by 
a steep learning curve and about 7% crossover rate to the 
femoral route. Procedural and fluoroscopy times are slightly 
longer compared to femoral approach, but as experience ac-
cumulates the difference becomes insignificant. The radial 
approach increases patient comfort and decreases hospitali-
zation time and cost. However, its most important feature is 
that it minimizes major bleeding by nearly abolishing serious 
access site complications. The evidence base that is currently 
available supports a wider application of the radial approach 
for most PCI procedures with the aim of improving outcomes 
by reduction in access site bleeding.
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